Literature DB >> 25296868

Characterization of susceptibility variants of influenza virus grown in the presence of T-705.

Tohru Daikoku1, Yoshihiro Yoshida, Tomoko Okuda, Kimiyasu Shiraki.   

Abstract

T-705 (favipiravir) is a potent inhibitor of RNA polymerases of influenza viruses. Susceptibility variants were isolated during passages in the presence of T-705. Nine variants with 0.4 to 2.1 times the 50% inhibitory concentration for plaque formation of the parent A/PR/8/34 (H1N1) strain had amino acid variations in the PB1, PB2, and PA genes of the RNA polymerase complex. However, the variation patterns in the RNA polymerase complex indicated that T-705 does not work as a mutagen, and resistant mutants were not isolated, possibly because a mutation leading to resistance would be lethal to the RNA polymerase function.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25296868     DOI: 10.1254/jphs.14156sc

Source DB:  PubMed          Journal:  J Pharmacol Sci        ISSN: 1347-8613            Impact factor:   3.337


  9 in total

1.  Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia.

Authors:  Mart Toots; Jeong-Joong Yoon; Robert M Cox; Michael Hart; Zachary M Sticher; Negar Makhsous; Roland Plesker; Alec H Barrena; Prabhakar G Reddy; Deborah G Mitchell; Ryan C Shean; Gregory R Bluemling; Alexander A Kolykhalov; Alexander L Greninger; Michael G Natchus; George R Painter; Richard K Plemper
Journal:  Sci Transl Med       Date:  2019-10-23       Impact factor: 17.956

2.  Interface-based design of the favipiravir-binding site in SARS-CoV-2 RNA-dependent RNA polymerase reveals mutations conferring resistance to chain termination.

Authors:  Aditya K Padhi; Jagneshwar Dandapat; Prakash Saudagar; Vladimir N Uversky; Timir Tripathi
Journal:  FEBS Lett       Date:  2021-09-01       Impact factor: 3.864

3.  A Novel Endonuclease Inhibitor Exhibits Broad-Spectrum Anti-Influenza Virus Activity In Vitro.

Authors:  Jeremy C Jones; Bindumadhav M Marathe; Christian Lerner; Lukas Kreis; Rodolfo Gasser; Philippe Noriel Q Pascua; Isabel Najera; Elena A Govorkova
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

Review 4.  Influenza virus polymerase inhibitors in clinical development.

Authors:  Frederick G Hayden; Nahoko Shindo
Journal:  Curr Opin Infect Dis       Date:  2019-04       Impact factor: 4.915

5.  Lethal Mutagenesis of Rift Valley Fever Virus Induced by Favipiravir.

Authors:  Belén Borrego; Ana I de Ávila; Esteban Domingo; Alejandro Brun
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

6.  Favipiravir Inhibits Hepatitis A Virus Infection in Human Hepatocytes.

Authors:  Reina Sasaki-Tanaka; Toshikatsu Shibata; Hiroaki Okamoto; Mitsuhiko Moriyama; Tatsuo Kanda
Journal:  Int J Mol Sci       Date:  2022-02-27       Impact factor: 5.923

7.  Combinations of Oseltamivir and T-705 Extend the Treatment Window for Highly Pathogenic Influenza A(H5N1) Virus Infection in Mice.

Authors:  Bindumadhav M Marathe; Sook-San Wong; Peter Vogel; Fernando Garcia-Alcalde; Robert G Webster; Richard J Webby; Isabel Najera; Elena A Govorkova
Journal:  Sci Rep       Date:  2016-05-25       Impact factor: 4.379

8.  The mechanism of resistance to favipiravir in influenza.

Authors:  Daniel H Goldhill; Aartjan J W Te Velthuis; Robert A Fletcher; Pinky Langat; Maria Zambon; Angie Lackenby; Wendy S Barclay
Journal:  Proc Natl Acad Sci U S A       Date:  2018-10-23       Impact factor: 11.205

Review 9.  Favipiravir, an anti-influenza drug against life-threatening RNA virus infections.

Authors:  Kimiyasu Shiraki; Tohru Daikoku
Journal:  Pharmacol Ther       Date:  2020-02-22       Impact factor: 12.310

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.